Seminars in Nephrology
Volume 24, Issue 3 , Pages 225-243 , May 2004

The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy

  • James V Donadio

      Affiliations

    • Corresponding Author InformationAddress reprint requests to James V. Donadio, MD, Mayo Clinic, 200 First Street SW, Stabile 722, Rochester, MN 55905, USA
    • Division of Nephrology, the Department of Medicine, and the Department of Laboratory Medicine and Pathology, Mayo Clinic & Mayo Foundation, Rochester, MN, USA
    • ,
  • Joseph P Grande

      Affiliations

    • Division of Nephrology, the Department of Medicine, and the Department of Laboratory Medicine and Pathology, Mayo Clinic & Mayo Foundation, Rochester, MN, USA

References 

  1. Donadio JV, Bergstralh EJ, Offord KP, et al.  A controlled trial of fish oil in IgA nephropathy. N Engl J Med. 1994;331:1194–1199
  2. Donadio J, Grande J, Bergstralh E, et al.  The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol. 1999;10:1772–1777
  3. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy. Lancet. 1984;1:1017–1018
  4. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentaenoic acid (EPA) (A two year prospective trial). Clin Nephrol. 1989;31:128–131
  5. Pettersson EE, Rekola S, Berglund L, et al.  Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids (A prospective, double-blind, randomized study). Clin Nephrol. 1994;41:183–190
  6. Donadio JV, Larson TS, Bergstralh EJ, et al.  A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001;12:791–799
  7. Holman R. Essential fatty acid deficiency. Prog Chem Fats Other Lipids. 1971;9:275–348
  8. Holman RT. Biological activities and requirements for polyunsaturated fatty acids. Prog Chem Fats Other Lipids. 1971;9:607–682
  9. Rieckehoff I, Holman RT, Burr G. Polyethenoid fatty acid metabolism (Effect of dietary fat on polyethenoid fatty acids of rat tissues). Arch Biochem. 1949;20:331–340
  10. Crawford MA. Background to essential fatty acids and their prostanoid derivatives. British Medical Bulletin. 1983;39:210–213
  11. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. Circulation. 1996;94:2337–2340
  12. Department of Health and Human Services, US Food and Drug Administration. . Substances affirmed as generally recognized as safe (Menhaden oil). Federal Register. 1997;62:30751–30757
  13. Office of Nutritional Products, Labeling, and Dietary Supplements Center for Food Safety and Applied Nutrition, US Food and Drug Administration . Letter responding to a request to reconsider the qualified claim for a dietary supplement health claim for omega-3 fatty acids and coronary heart disease. 2002; Docket No. 91N-0103
  14. Holman RT. Nutritional and metabolic interrelationships between fatty acids. Fed Proc. 1964;23:1062–1067
  15. Holman RT. Control of polyunsaturated acids in tissue lipids. J Am Coll Nutr. 1986;5:183–211
  16. Kris-Etherton P, Shaffer Taylor D, Yu-Poth S, et al.  Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71:179S–188S
  17. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70:560S–569S
  18. Simopoulos AP, Leaf A, Salem N. Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab. 1999;43:127–130
  19. Dietary Reference Intakes for Energy and Macronutrients. Washington, DC: Institute of Medicine (IOM), National Academy Press; 2002;
  20. Berger J, Hinglais N. Les depots intercapillaires d’IgA-IgG. J Urol Nephrol. 1968;74:694–695
  21. Donadio JV, Grande JP. Immunoglobulin A nephropathy (A clinical perspective). J Am Soc Nephrol. 1997;8:1324–1332
  22. Radford MG, Donadio JV, Bergstralh EJ, et al.  Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207
  23. Ibels LS, Gyory AZ. IgA nephropathy (Analysis of the natural history, important factors in the progression of renal disease, and a review of the literature). Medicine. 1994;73:79–102
  24. Beukhof JR, Kardaun O, Schaafsma W, et al.  Toward individual prognosis of IgA nephropathy. Kidney Int. 1986;29:549–556
  25. Duarte CG, Preuss HG. Assessment of renal function-glomerular and tubular. Clin Lab Med. 1993;13:33–51
  26. Bumgardner GL, Amend WC, Ascher NL, et al.  Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation. 1998;65:1053–1060
  27. Ponticelli C, Traversi L, Feliciani A, et al.  Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int. 2001;60:1948–1954
  28. Berger J. Recurrence of IgA nephropathy in renal allografts. Am J Kidney Dis. 1988;12:371–372
  29. Kim YS, Jeong HJ, Choi KH, et al.  Renal transplantation in patients with IgA nephropathy. Transplant Proc. 1996;28:1543–1544
  30. Frohnert PP, Donadio JV, Velosa JA, et al.  The fate of renal transplants in patients with IgA nephropathy. Clin Transplant. 1997;11:127–133
  31. Ohmacht C, Kliem V, Burg M, et al.  Recurrent immunoglobulin A nephropathy after renal transplantation. A significant contributor to graft loss. Transplantation. 1997;64:1493–1496
  32. Koselj M, Rott T, Kandus A, et al.  Donor-transmitted IgA nephropathy (Long-term follow-up of kidney donors and recipients). Transplant Proc. 1997;29:3406–3407
  33. Silva FG, Chander P, Pirani CL, et al.  Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation. 1982;33:241–246
  34. Feehally J. IgA nephropathyA disorder of IgA production?. Q J Med. 1997;90:387–390
  35. Launay P, Grossetete B, Arcos-Fajardo M, et al.  Fca receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med. 2000;191:1999–2009
  36. Jennette JC, Wieslander J, Tuttle R, et al.  Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura (Diagnostic value and pathogenic implications). Am J Kidney Dis. 1991;18:466–471
  37. Hall RP, Stachura I, Cason J, et al.  IgA-containing circulating immune complexes in patients with IgA nephropathy. Am J Med. 1983;74:56–63
  38. Coppo R, Amore A, Cirina P, et al.  Characteristics of IgA and macromolecular IgA in sera from IgA nephropathy transplanted patients with and without IgAN recurrence. Contrib Nephrol. 1995;111:85–92
  39. Galla JH. IgA nephropathy. Kidney Int. 1995;47:377–387
  40. Layward L, Allen AC, Hattersley JM, et al.  Elevation of IgA in IgA nephropathy is localized in the serum and not saliva and is restricted to the IgA1 subclass. Nephrol Dial Transplant. 1993;8:25–28
  41. Russell MW, Mestecky J, Julian BA, et al.  IgA-associated renal diseases (Antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli). J Clin Immunol. 1986;6:74–86
  42. Buck KS, Foster EM, Watson D, et al.  Expression of T cell receptor variable region families by bone marrow gd T cells in patients with IgA nephropathy. Clin Exp Immunol. 2002;127:527–532
  43. Layward L, Finnemore A-M, Allen AC, et al.  Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy. Clin Immunol Immunopathol. 1993;69:306–313
  44. Mestecky J, Tomana M, Crowley-Nowick PA, et al.  Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol. 1993;104:172–182
  45. Kilgore LL, Patterson BW, Parenti DM, et al.  Immune complex hyperlipidemia induced by an apolipoprotein-reactive immunoglobulin A paraprotein from a patient with multiple myeloma. Characterization of this immunoglobulin. J Clin Invest. 1985;76:225–232
  46. Bene MC, Canton P, Amiel C, et al.  Absence of mesangial IgA in AIDS (A postmortem study). Nephron. 1991;58:240–241
  47. Suzuki S, Fujieda S, Sunaga H, et al.  Immune response of tonsillar lymphocytes to Haemophilus parainfluenzae in patients with IgA nephropathy. Clin Exp Immunol. 2000;119:328–332
  48. Bene MC, Faure GC. Mesangial IgA in IgA nephropathy arises from the mucosa. Am J Kidney Dis. 1988;12:406–409
  49. Kovacs T, Kun L, Schmelczer M, et al.  Do intestinal hyperpermeability and the related food antigens play a role in the progression of IgA nephropathy? I. Study of intestinal permeability. Am J Nephrol. 1996;16:500–505
  50. Feehally J, Allen AC. Pathogenesis of IgA nephropathy. Ann Med Interne (Paris). 1999;150:91–98
  51. Olive C, Allen AC, Harper SJ, et al.  Expression of the mucosal gamma delta T cell receptor V region repertoire in patients with IgA nephropathy. Kidney Int. 1997;52:1047–1053
  52. Harper SJ, Pringle JH, Wicks AC, et al.  Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int. 1994;45:836–844
  53. Allen A, Harper S, Feehally J. Origin and structure of pathogenic IgA in IgA nephropathy. Biochem Soc Trans. 1997;25:486–490
  54. Mestecky J, Russell MW, Jackson S, et al.  The human IgA system (a reassessment). Clin Immunol Immunopathol. 1986;40:105–114
  55. Greer MR, Barratt J, Harper SJ, et al.  The nucleotide sequence of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transplant. 1998;13:1980–1983
  56. Field MC, Dwek RA, Edge CJ, et al.  O-linked oligosaccharides from human serum immunoglobulin A1. Biochem Soc Trans. 1989;17:1034–1035
  57. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995;100:470–474
  58. Allen AC, Willis FR, Beattie TJ, et al.  Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant. 1998;13:930–934
  59. Tomana M, Matousovic K, Julian BA, et al.  Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 1997;52:509–516
  60. Allen AC, Bailey EM, Brenchley PE, et al.  Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation (Observations in three patients). Kidney Int. 2001;60:969–973
  61. Allen AC, Topham PS, Harper SJ, et al.  Leukocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant. 1997;12:701–706
  62. Scivittaro V, Gesualdo L, Ranieri E, et al.  Profiles of immunoregulatory cytokine production in vitro in patients with IgA nephropathy and their kindred. Clin Exp Immunol. 1994;96:311–316
  63. Scivittaro V, Ranieri E, Di Cillo M, et al.  In vitro immunoglobulin production in relatives of patients with IgA nephropathy. Clin Nephrol. 1994;42:1–8
  64. Lai KN. The cellular immunity and nature of IgA molecules in IgA nephropathy. Contrib Nephrol. 1993;104:99–111
  65. Lai KN, Ho RT, Leung JC, et al.  CD4-positive cells from patients with IgA nephropathy demonstrate increased mRNA of cytokines that induce the IgA switch and differentiation. J Pathol. 1994;174:13–22
  66. Chintalacharuvu SR, Emancipator SN. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol. 1997;159:2327–2333
  67. Leung JC, Tang SC, Chan DT, et al.  Increased sialylation of polymeric l-IgA1 in patients with IgA nephropathy. J Clin Lab Anal. 2002;16:11–19
  68. Chintalacharuvu SR, Nagy NU, Sigmund N, et al.  T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation. Clin Exp Immunol. 2001;126:326–333
  69. Roccatello D, Picciotto G, Torchio M, et al.  Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Lab Invest. 1993;69:714–723
  70. Mestecky J, Hashim OH, Tomana M. Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1. Contrib Nephrol. 1995;111:66–71
  71. Tomana M, Kulhavy R, Mestecky J. Receptor-mediated binding and uptake of immunoglobulin A by human liver. Gastroenterology. 1988;94:762–770
  72. Stockert RJ, Kressner MS, Collins JC, et al.  IgA interaction with the asialoglycoprotein receptor. Proc Natl Acad Sci U S A. 1982;79:6229–6231
  73. Gomez-Guerrero C, Gonzalez E, Egido J. Evidence for a specific IgA receptor in rat and human mesangial cells. J Immunol. 1993;151:7172–7181
  74. Moura IC, Centelles MN, Arcos-Fajardo M, et al.  Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med. 2001;194:417–425
  75. Chen A, Chen W-P, Sheu L-F, et al.  Pathogenesis of IgA nephropathy (In vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion). J Pathol. 1994;173:119–126
  76. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, et al.  Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha, IL-6, and proliferation. J Immunol. 1994;153:5247–5255
  77. Niemir ZI, Stein H, Noronha IL, et al.  PDGF and TGF-b contribute to the natural course of human IgA glomerulonephritis. Kidney Int. 1995;48:1530–1541
  78. Taniguchi Y, Yorioka N, Oda H, et al.  Platelet-derived growth factor, interleukin (IL)-1 beta, IL-6R and tumor necrosis factor-alpha in IgA nephropathy. An immunohistochemical study. Nephron. 1996;74:652–660
  79. Cheng JJ, Grande JP. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med. 2002;227:943–956
  80. Yoshioka K, Takemura T, Murakami K, et al.  Transforming growth factor-b protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest. 1993;68:154–163
  81. Taniguchi Y, Yorioka N, Masaki T, et al.  Localization of transforming growth factors b1 and b2 and epidermal growth factor in IgA nephropathy. Scand J Urol Nephrol. 1999;33:243–247
  82. Albert CM, Campos H, Stampfer MJ, et al.  Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346:1113–1118
  83. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757
  84. Albert CM, Hennekens CH, O’Donnell CJ, et al.  Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23–28
  85. Nordoy A, Marchioli R, Arnesen H, et al.  n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids. 2001;36:S127–129
  86. GISSI-Prevenzione Investigators . Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction (results of the GISSI-Prevenzione trial). Lancet. 1999;354:447–455
  87. von Schacky C, Angerer P, Kothny W, et al.  The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130:554–562
  88. Madsen T, Skou HA, Hansen VE, et al.  C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol. 2001;88:1139–1142
  89. Pepe S, McLennan PL. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr. 1996;126:34–42
  90. McLennan PL. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids. 2001;36:S111–114
  91. Lemaitre RN, King IB, Mozaffarian D, et al.  n-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults (The Cardiovascular Health Study). Am J Clin Nutr. 2003;77:319–325
  92. Pownall HJ, Brauchi D, Kilinc C, et al.  Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285–297
  93. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34–42
  94. Harris WS. n-3 fatty acids and serum lipoproteins (human studies). Am J Clin Nutr. 1997;65:1645S–1654S
  95. Dionisio P, Caramello E, Bergia R, et al.  Atherogenic risk in patients undergoing regular dialysis treatment (Improvement of lipid pattern and lipoproteins by polyunsaturated omega-3 fatty acids). Nephrol Dial Transplant. 1994;9:458
  96. Phillipson BE, Rothrock DW, Connor WE, et al.  Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med. 1985;312:1210–1216
  97. Clark WF, Parbtani A, Huff MW, et al.  Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int. 1989;36:653–660
  98. Khan S, Minihane AM, Talmud PJ, et al.  Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002;43:979–985
  99. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993;88:523–533
  100. Geleijnse JM, Giltay EJ, Grobbee DE, et al.  Blood pressure response to fish oil supplementation (Metaregression analysis of randomized trials). J Hypertens. 2002;20:1493–1499
  101. Frenoux JM, Prost ED, Belleville JL, et al.  A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. J Nutr. 2001;131:39–45
  102. Kimura S, Minami M, Saito H, et al.  Dietary docosahexaenoic acid (22:6n-3) prevents the development of hypertension in SHRSP. Clin Exp Pharmacol Physiol. 1995;22(suppl 1):S308–309
  103. Hobbs LM, Rayner TE, Howe PRC. Dietary fish oil prevents the development of renal damage in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1996;23:508–513
  104. Engler MB, Engler MM. Docosahexaenoic acid-induced vasorelaxation in hypertensive rats (Mechanisms of action). Biol Res Nurs. 2000;2:85–95
  105. Engler M, Ma Y, Engler M. Calcium-mediated mechanisms of eicosapentaenoic acid-induced relaxation in hypertensive rat aorta. Am J Hypertens. 1999;12:1225–1235
  106. Hirafuji M, Ebihara T, Kawahara F, et al.  Effect of docosahexaenoic acid on smooth muscle cell functions. Life Sci. 1998;62:1689–1693
  107. Nestel P, Shige H, Pomeroy S, et al.  The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr. 2002;76:326–330
  108. Mori TA, Watts GF, Burke V, et al.  Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation. 2000;102:1264–1269
  109. Schmitz PG, McCloud LK, Reikes ST, et al.  Prophylaxis of hemodialysis graft thrombosis with fish oil (Double-blind, randomized, prospective trial). J Am Soc Nephrol. 2002;13:184–190
  110. Driss F, Vericel E, Lagarde M, et al.  Inhibition of platelet aggregation and thromboxane synthesis after intake of small amount of eicosapentaenoic acid. Thromb Res. 1984;36:389–396
  111. Skeaff CM, Holub BJ. The effect of fish oil consumption on platelet aggregation responses in washed human platelet suspensions. Thromb Res. 1988;51:105–115
  112. Agren JJ, Vaisanen S, Hanninen O, et al.  Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 1997;57:419–421
  113. Mori TA, Beilin LJ, Burke V, et al.  Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997;17:279–286
  114. Sethi S, Ziouzenkova O, Ni H, et al.  Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARa. Blood. 2002;100:1340–1346
  115. Mayer K, Merfels M, Muhly-Reinholz M, et al.  Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells (role of endothelial PAF generation). Am J Physiol Heart Circ Physiol. 2002;283:H811–818
  116. De Caterina R, Libby P. Control of endothelial leukocyte adhesion molecules by fatty acids. Lipids. 1996;31(suppl):S57–63
  117. Seljeflot I, Arnesen H, Brude IR, et al.  Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur J Clin Invest. 1998;28:629–635
  118. Collie-Duguid ESR, Wahle KWJ. Inhibitory effect of fish oil n-3 polyunsaturated fatty acids on the expression of endothelial cell adhesion molecules. Biochem Biophys Res Commun. 1996;220:969–974
  119. Prickett JD, Robinson DR, Steinberg AD. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB X NZW F1 mice. J Clin Invest. 1981;68:556–559
  120. Prickett JD, Robinson DR, Steinberg AD. Effects of dietary enrichment with eicosapentaenoic acid upon autoimmune nephritis in female NZB x NZW/F1 mice. Arthritis Rheum. 1983;26:133–139
  121. Robinson DR, Prickett JD, Makoul GT, et al.  Dietary fish oil reduces progression of established renal disease in (NZB x NZW)F1 mice and delays renal disease in BXSB and MRL/1 strains. Arthritis Rheum. 1986;29:539–546
  122. Grande J, Walker H, Holub B, et al.  Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int. 2000;57:1027–1040
  123. Brown SA, Brown CA, Crowell WA, et al.  Beneficial effects of chronic administration of dietary omega-3 polyunsaturated fatty acids in dogs with renal insufficiency. J Lab Clin Med. 1998;131:447–455
  124. De Caterina R, Caprioli R, Giannessi D, et al.  n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney Int. 1993;44:843–850
  125. Branten AJ, Klasen IS, Wetzels JF. Short-term effects of fish oil treatment on urinary excretion of high- and low-molecular weight proteins in patients with IgA nephropathy. Clin Nephrol. 2002;58:267–274
  126. Uauy R, Mena P, Valenzuela A. Essential fatty acids as determinants of lipid requirements in infants, children and adults. Eur J Clin Nutr. 1999;53(suppl 1):S66–77
  127. Fischer S, Weber PC. Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature. 1984;307:165–168
  128. Fischer S, Weber PC. Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem Biophys Res Commun. 1983;116:1091–1099
  129. Bayon Y, Croset M, Daveloose D, et al.  Effect of specific phospholipid molecular species incorporated in human platelet membranes on thromboxane A2/prostaglandin H2 receptors. J Lipid Res. 1995;36:47–56
  130. Scharschmidt LA, Lianos E, Dunn MJ. Arachidonate metabolites and the control of glomerular function. Fed Proc. 1983;42:3058–3063
  131. Sakr HM, Dunham EW. Mechanism of arachidonic acid-induced vasoconstriction in the intact rat kidney (Possible involvement of thromboxane A2). J Pharmacol Exp Ther. 1982;221:614–622
  132. Endoh M, Kashem A, Yamauchi F, et al.  Expression of thromboxane synthase in kidney tissues from patients with IgA nephropathy. Clin Nephrol. 1997;47:168–175
  133. Rifai A, Sakai H, Yagame M. Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis. Kidney Int. 1993;39:S95–S99
  134. Engstrom K, Wallin R, Saldeen T. Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids. Prostaglandins Leukot Essent Fatty Acids. 2001;64:291–297
  135. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr. 2002;56(suppl 3):S14–S19
  136. Schmitz PG, Zhang K, Dalal R. Eicosapentaenoic acid suppresses PDGF-induced DNA synthesis in rat mesangial cells (involvement of thromboxane A2). Kidney Int. 2000;57:1041–1051
  137. Nitta K, Uchida K, Tsutsui T, et al.  Eicosapentaenoic acid inhibits mitogen-induced endothelin-1 production and DNA synthesis in cultured bovine mesangial cells. Am J Nephrol. 1998;18:164–170
  138. Pakala R, Pakala R, Benedict C. Eicosapentaenoic acid and docosahexaenoic acid selectively attenuate U46619-induced smooth muscle cell proliferation. Lipids. 1999;34:915–920
  139. Pakala R, Benedict C. Thromboxane A2 fails to induce proliferation of smooth muscle cells enriched with eicosapentaenoic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids. 1999;60:275–281
  140. Pakala R, Sheng W, Benedict C. Eicosapentaenoic acid and docosahexaenoic acid block serotonin-induced smooth muscle cell proliferation. Arterioscler Thromb. 1999;19:2316–2322
  141. Tessier C, Fayard J-M, Cohen H, et al.  Docosahexaenoic acid is a potent inhibitor of rat uterine stromal cell proliferation. Biochem Biophys Res Commun. 1995;207:1015–1021
  142. Shiina T, Terano T, Saito J, et al.  Eicosapentaenoic acid and docosahexaenoic acid suppress the proliferation of vascular smooth muscle cells. Atherosclerosis. 1993;104:95–103
  143. Diep QN, Intengan HD, Schiffrin EL. Endothelin-1 attenuates w3 fatty acid-induced apoptosis by inhibition of caspase 3. Hypertension. 2000;35:287–291
  144. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension. 2000;36:851–855
  145. Chen ZY, Istfan NW. Docosahexaenoic acid is a potent inducer of apoptosis in HT-29 colon cancer cells. Prostaglandins Leukot Essent Fatty Acids. 2000;63:301–308
  146. Siddiqui RA, Jenski LJ, Neff K, et al.  Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process. Biochim Biophys Acta. 2001;1499:265–275
  147. Kim HY, Akbar M, Lau A, et al.  Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem. 2000;275:35215–35223
  148. Yano M, Kishida E, Iwasaki M, et al.  Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor. J Nutr. 2000;130:1095–1101
  149. Kishida E, Yano M, Kasahara M, et al.  Distinctive inhibitory activity of docosahexaenoic acid against sphingosine-induced apoptosis. Biochim Biophys Acta. 1998;1391:401–408
  150. Yusufi A, Cheng J, Thompson M, et al.  Differential effects of low-dose docosahexa enoicacid and eicusapentaenoic acid on regulation of mitogenic signaling pathways in mesangial cells. J Lab Clin Med. 2003;141:318–329
  151. Davis R. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem. 1993;268:14553–14556
  152. Davis R. MAPKs (new JNK expands the group). Trends Biochem Sci. 1994;18:470–473
  153. Sherr CJ. G1 phase progression (cycling on cue). Cell. 1994;79:551–555
  154. Sherr CJ. Mammalian G1 cyclins. Cell. 1993;73:1059–1065
  155. Shankland SJ. Cell-cycle control and renal disease. Kidney Int. 1997;52:294–308
  156. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131–134
  157. Lundberg A, Weinberg R. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18:753–761
  158. Kitagawa M, Higashi H, Jung H, et al.  The consensus motif for phosphorylation by cyclin D1-cdk4 is different from that for phosphorylation by cyclin A/E-cdk2. EMBO J. 1996;15:7060–7069
  159. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem. 1992;61:441–470
  160. Terano T, Tanaka T, Tamura Y, et al.  Eicosapentaenoic acid and docosahexaenoic acid inhibit vascular smooth muscle cell proliferation by inhibiting phosphorylation of Cdk2-cyclinE complex. Biochem Biophys Res Commun. 1999;254:502–506
  161. Chen ZY, Istfan NW. Docosahexaenoic acid, a major constituent of fish oil diets, prevents activation of cyclin-dependent kinases and S-phase entry by serum stimulation in HT-29 cells. Prostaglandins Leukot Essent Fatty Acids. 2001;64:67–73
  162. Chiu LC, Ooi VE, Wan JM. Eicosapentaenoic acid modulates cyclin expression and arrests cell cycle progression in human leukemic K-562 cells. Int J Oncol. 2001;19:845–849
  163. Johnson D, Walker C. Cyclins and cell cycle checkpoints. Ann Rev Pharmacol. 1999;39:295–312
  164. Rao R. Targets for cancer therapy in the cell cycle pathway. Curr Opin Oncol. 1996;8:516–524
  165. Yoshioka K, Takemura T, Murakami K, et al.  In situ expression of cytokines in IgA nephritis. Kidney Int. 1993;44:825–833
  166. Yano N, Endoh M, Nomoto Y, et al.  Phenotypic characterization of cytokine expression in patients with IgA nephropathy. J Clin Immunol. 1997;17:396–403
  167. Ballardie FW, Gordon MT, Sharpe PT, et al.  Intrarenal cytokine mRNA expression and location in normal and IgA nephropathy tissue (TGFa, TGFb, IGF 1, IL-4 and IL-6). Nephrol Dial Transplant. 1994;9:1545–1552
  168. Lim CS, Zheng S, Kim YS, et al.  Th1/Th2 predominance and proinflammatory cytokines determine the clinicopathological severity of IgA nephropathy. Nephrol Dial Transplant. 2001;16:269–275
  169. Li H-L, Hancock WW, Dowling JP, et al.  Activated (IL-2R+) intraglomerular mononuclear cells in crescentic glomerulonephritis. Kidney Int. 1991;39:793–798
  170. Wu T-H, Wu S-C, Huang T-P, et al.  Increased excretion of tumor necrosis factor alpha and interleukin 1b in urine from patients with IgA nephropathy and Schönlein-Henoch purpura. Nephron. 1996;74:79–88
  171. Yokoyama H, Takaeda M, Wada T, et al.  Intraglomerular expression of MHC class II and Ki-67 antigens and serum gamma-interferon levels in IgA nephropathy. Nephron. 1992;62:169–175
  172. Calder PC, Yaqoob P, Thies F, et al.  Fatty acids and lymphocyte functions. Br J Nutr. 2002;87(suppl 1):S31–48
  173. Endres S, Ghorbani R, Kelley VE, et al.  The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320:265–271
  174. Schneider SM, Fung VS, Palmblad J, et al.  Activity of the leukocyte NADPH oxidase in whole neutrophils and cell- free neutrophil preparations stimulated with long-chain polyunsaturated fatty acids. Inflammation. 2001;25:17–23
  175. Grimble RF, Howell WM, O’Reilly G, et al.  The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr. 2002;76:454–459
  176. Novak TE, Babcock TA, Jho DH, et al.  NF-kB inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-a transcription. Am J Physiol Lung Cell Mol Physiol. 2003;284:L84–L89
  177. Bagheri N, Chintalacharuvu SR, Emancipator SN. Proinflammatory cytokines regulate Fc alphaR expression by human mesangial cells in vitro. Clin Exp Immunol. 1997;107:404–409
  178. Duque N, Gomez-Guerrero C, Egido J. Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol. 1997;159:3474–3482
  179. Ranieri E, Gesualdo L, Petrarulo F, et al.  Urinary IL-6/EGF ratio (a useful prognostic marker for the progression of renal damage in IgA nephropathy). Kidney Int. 1996;50:1990–2001
  180. Tomino Y, Funabiki K, Ohmuro H, et al.  Urinary levels of interleukin-6 and disease activity in patients with IgA nephropathy. Am J Nephrol. 1991;11:459–464
  181. Dohi K, Iwano M, Muraguchi A, et al.  The prognostic significance of urinary interleukin 6 in IgA nephropathy. Clin Nephrol. 1991;35:1–5
  182. Khalfoun B, Thibault F, Watier H, et al.  Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol. 1997;400B:589–597
  183. Jeyarajah DR, Kielar M, Penfield J, et al.  Docosahexaenoic acid, a component of fish oil, inhibits nitric oxide production in vitro. J Surg Res. 1999;83:147–150
  184. Boutard V, Fouqueray B, Philippe C, et al.  Fish oil supplementation and essential fatty acid deficiency reduce nitric oxide synthesis by rat macrophages. Kidney Int. 1994;46:1280–1286
  185. Sperling RI, Robin J-L, Kylander KA, et al.  The effects of n-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol. 1987;139:4186–4191
  186. Kaminski WE, Jendraschak E, Kiefl R, et al.  Dietary w-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood. 1993;81:1871–1879
  187. Nguyen TT, Shou I, Funabiki K, et al.  Correlations among expression of glomerular intercellular adhesion molecule 1 (ICAM-1), levels of serum soluble ICAM-1, and renal histopathology in patients with IgA nephropathy. Am J Nephrol. 1999;19:495–499
  188. Fox PL, DiCorleto PE. Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science. 1988;241:453–456
  189. Bagchus WM, Hoedemaeker PJ, Rozing J, et al.  Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. Lab Invest. 1986;55:680–687
  190. Bagchus WM, Jeunink MF, Elema JD. The mesangium in anti-Thy-1 nephritis. Influx of macrophages, mesangial cell hypercellularity, and macromolecular accumulation. Am J Pathol. 1990;137:215–223
  191. Floege J, Eng E, Young BA, et al.  Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int. 1993;43:S47–S54
  192. Floege J, Johnson RJ, Gordon K, et al.  Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 1991;40:477–488
  193. Johnson RJ. The glomerular response to injury (Progression or resolution?). Kidney Int. 1994;45:1769–1782
  194. Pestka JJ, Dong W, Warner RL, et al.  Effect of dietary administration of the trichothecene vomitoxin (deoxynivalenol) on IgA and IgG secretion by Peyer’s patch and splenic lymphocytes. Food Chem Toxicol. 1990;28:693–699
  195. Pestka JJ, Dong W, Warner RL, et al.  Elevated membrane IgA+ and CD4+ (T helper) populations in murine Peyer’s patch and splenic lymphocytes during dietary administration of the trichothecene vomitoxin (deoxynivalenol). Food Chem Toxicol. 1990;28:409–420
  196. Pestka JJ, Moorman MA, Warner RL. Dysregulation of IgA production and IgA nephropathy induced by the trichothecene vomitoxin. Food Chem Toxicol. 1989;27:361–368
  197. Pestka JJ, Zhou HR, Jia Q, et al.  Dietary fish oil suppresses experimental immunoglobulin a nephropathy in mice. J Nutr. 2002;132:261–269
  198. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347:738–748
  199. Dillon JJ. Fish oil therapy for IgA nephropathy (Efficacy and interstudy variability). J Am Soc Nephrol. 1997;8:1739–1744
  200. Julian BA. Treatment of IgA nephropathy. Semin Nephrol. 2000;20:277–285
  201. Maschio G, Cagnoli L, Claroni F, et al.  ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy (A multicentre, randomized, placebo-controlled study). Nephrol Dial Transplant. 1994;9:265–269
  202. Bannister KM, Weaver A, Clarkson AR, et al.  Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol. 1995;111:184–192
  203. Cheng I, Fang G, Wong M, et al.  A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology. 1998;4:19–26
  204. Cattran DC, Greenwood C, Ritchie S. Long-term benefit of angiotensin-converting-enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy (A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy). Am J Kidney Dis. 1994;23:247–254
  205. Holman RT, Johnson SB, Bibus D, et al.  Essential fatty acid deficiency profiles in idiopathic immunoglobulin A nephropathy. Am J Kidney Dis. 1994;23:648–654
  206. In: Omacor™Immunoglobulin A Nephropathy, Product Manager Resource Manual. London: OCC Europe Ltd; 2001;p. 1–98
  207. Calder PC. n-3 polyunsaturated fatty acids and cytokine production in health and disease. Ann Nutr Metab. 1997;41:203–234
  208. Kumaratilake LM, Ferrante A, Robinson BS, et al.  Enhancement of neutrophil-mediated killing of Plasmodium falciparum asexual blood forms by fatty acids (Importance of fatty acid structure). Infect Immun. 1997;65:4152–4157
  209. Costabile M, Hii CS, Robinson BS, et al.  A novel long chain polyunsaturated fatty acid, b-Oxa 21:3n-3, inhibits T lymphocyte proliferation, cytokine production, delayed-type hypersensitivity, and carrageenan-induced paw reaction and selectively targets intracellular signals. J Immunol. 2001;167:3980–3987
  210. Nielsen GL, Faarvang KL, Thomsen BS, et al.  The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis (A randomized, double blind trial). Eur J Clin Invest. 1992;22:687–691
  211. Gallai V, Sarchielli P, Trequattrini A, et al.  Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol. 1995;56:143–153
  212. Molvig J, Pociot F, Worsaae H, et al.  Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 beta content but not monokine secretion in healthy and insulin-dependent diabetic individuals. Scand J Immunol. 1991;34:399–410
  213. Soyland E, Lea T, Sandstad B, et al.  Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen- stimulated lymphocytes from patients with inflammatory skin diseases. Eur J Clin Invest. 1994;24:236–242
  214. Ferrante JV, Huang ZH, Nandoskar M, et al.  Altered responses of human macrophages to lipopolysaccharide by hydroperoxy eicosatetraenoic acid, hydroxy eicosatetraenoic acid, and arachidonic acid. Inhibition of tumor necrosis factor production. J Clin Invest. 1997;99:1445–1452
  215. Keli SO, Feskens EJ, Kromhout D. Fish consumption and risk of stroke. The Zutphen Study. Stroke. 1994;25:328–332
  216. Hokenson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level (A meta-analysis of population-based prospective studies). J Cardiovasc Risk. 1996;3:213–219
  217. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol. 1992;2:1634–1639
  218. Jones W, Kaiser S. Pilot study (An emulsified fish oil supplement significantly improved c-reactive protein, hemoglobin, albumin, and urine output in chronic hemodialysis volunteers). Journal of the American Neutraceutical Association. 2002;5:45–50
  219. Peck LW, Monsen ER, Ahmad S. Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am J Clin Nutr. 1996;64:210–214
  220. Maachi K, Berthoux P, Burgard G, et al.  Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy. Transplant Proc. 1995;27:846–849
  221. Alexander JW. Role of immunonutrition in reducing complications following organ transplantation. Transplant Proc. 2000;32:574–575
  222. Kremer JM, Lawrence DA, Jubiz W, et al.  Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum. 1990;33:810–820
  223. Kremer JM, Lawrence DA, Petrillo GF, et al.  Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum. 1995;38:1107–1114
  224. Agricultural Research Service USDA (USDA Nutrient Database for Standard Reference, Release 15). 2003; Nutrient Data Laboratory Home Page. Available at: http://www.nal.usda.gov/fnic/foodcomp. Accessed March 27
  225. Donadio JV. Omega-3 polyunsaturated fatty acids (a potential new treatment of immune renal disease). Mayo Clin Proc. 1991;66:1018–1022
  226. Donadio JV. The emerging role of omega-3 polyunsaturated fatty acids in the management of patients with IgA nephropathy. J Renal Nutr. 2001;11:122–128

PII: S0270-9295(04)00006-3

doi: 10.1016/j.semnephrol.2004.01.004

Seminars in Nephrology
Volume 24, Issue 3 , Pages 225-243 , May 2004

Article Tools

* Image Usage & Resolution